Drug Profile
S 65487
Alternative Names: S 65487/VOB 560; S-65487; VOB-560Latest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator Servier; Vernalis
- Developer ADIR; Institut de Recherches Internationales Serviers; Novartis; Servier
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
- Phase I Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
Most Recent Events
- 11 Apr 2024 53466 S 65487 is still in I/II trials for Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Multiple Myeloma in France, United Kingdom, Spain, Australia (NCT03755154)
- 06 Nov 2023 ADIR completes a phase I trial in Multiple myeloma (Metastatic disease, Recurrent, Second-line therapy or greater), Acute myeloid leukaemia (Metastatic disease, Recurrent, Second-line therapy or greater) and Non-Hodgkin's lymphoma (Metastatic disease, Recurrent, Second-line therapy or greater) in France, United Kingdom, Spain, Australia (IV) (NCT03755154)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Metastatic disease, Recurrent, Second-line therapy or greater) in Australia (IV, Infusion)